VRTX Vertex Pharmaceuticals Incorporated

180.15
-0.87  -0%
Previous Close 181.02
Open 181.64
Price To Book 9.77
Market Cap 46,140,263,004
Shares 256,121,360
Volume 960,080
Short Ratio
Av. Daily Volume 1,219,632

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 positive data released November 27, 2018. 14% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min)
Label expanded to now include all patients over 6 years old - June 21, 2019.
Tezacaftor / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data released July 18, 2017. ppFEV1 of 12.0 percentage points.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
NDA filing due 1Q 2018.
ORKAMBI
Two Copies of the F508del Mutation - children ages 2 to 5
Phase 3 data released October 25, 2017 - primary endpoint not met.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation
Phase 2 data released July 18, 2017. ppFEV1 of 9.7 percentage points.
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data released December 18, 2018. Primary endpoint met.
VX-150
Neuropathic pain
Phase 2b data due 1H 2019.
VX-150
Acute pain following bunionectomy surgery
NDA filing due 3Q 2019.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have two copies of the F508del mutation
Phase 3 positive data released November 27, 2018. 10% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic Fibrosis Who Have Two Copies of the F508del Mutation
NDA filing due 3Q 2019.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation
Phase 1/2 trial first patient enrolled - noted February 25, 2019.
CTX001
Sickle cell disease
Phase 1/2 trial first patient infused - noted February 25, 2019.
CTX001
Beta-thalassemia
FDA Approval announced August 7, 2018.
Ivacaftor
Cystic fibrosis (CF) ages 2 to 5.
Approval announced August 15, 2018.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 1-2.
FDA Approval announced April 30, 2019.
Ivacaftor
Cystic Fibrosis (6-12 mths)
sNDA filing due late 2018.
Tezacaftor and ivacaftor
Cystic Fibrosis (Age 6-11)
Phase 2 monotherapy trial initiated 2Q 2019.
VX-561
Cystic fibrosis who have a gating mutation
Phase 2 combo trial initiated May 2019.
VX-561 and VX-121
Cystic Fibrosis

Latest News

  1. The 10 Biggest Biotech Stocks
  2. Playing with tech to create drug-free ADHD treatment
  3. Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children
  4. 3 Stocks That Could Double Your Money
  5. FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene
  6. 3 Big Biotechs Hold Growth Potential in Second Half of 2019
  7. Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $9.8 million of Shares
  8. The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
  9. Check Out These 5 Fast-Growing Stocks to Buy Today
  10. 7 Top-Rated Biotech Stocks to Invest In Today
  11. Glaxo Inks Genome Research Deal With University of California
  12. 3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics
  13. Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray
  14. Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
  15. 5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to Profit
  16. CELG or VRTX: Which Is the Better Value Stock Right Now?
  17. Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy?
  18. CRISPR Therapeutics Up on Collaboration Expansion by Vertex
  19. See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
  20. 3 Healthcare Stocks I'd Buy Right Now